文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

局部晚期子宫内膜癌化疗后大分割放疗的I期试验

Phase I De-escalated RT in Endometrial Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-01-21

这项I期试验评估局部晚期子宫内膜癌患者术后化疗序贯大分割放疗(25 Gy/5次)的安全性。25例患者中急性G3血液学毒性为12%,晚期G3血液学毒性为4%,无G3胃肠或泌尿毒性及G4-5毒性。中位随访24.7个月,1例野内复发,4例野外面主动脉旁复发,4例远处复发,2例癌症相关死亡。

要点

  • 化疗后大分割放疗25 Gy/5次方案在局部晚期子宫内膜癌中安全性可接受。
  • 急性G3胃肠、泌尿、血液学毒性分别为0%、0%、12%。
  • 晚期G3胃肠、泌尿、血液学毒性分别为0%、0%、4%,无G4-5毒性。

核心结论

  • 子宫切除术后辅助化疗序贯大分割放疗是安全的,高级别毒性低,值得在随机试验中评估。

研究设计与样本

  • I期试验(NCT#04386993)纳入25例FIGO 2009 III-IVA期子宫内膜样腺癌或任何期别的浆液性、透明细胞或癌肉瘤患者,均接受手术分期、辅助化疗后大分割放疗(调强放疗25 Gy/5次,每日照射阴道残端和骨盆)。

主要发现

  • 急性治疗相关G3胃肠、泌尿、血液学毒性发生率分别为0%(0/25)、0%(0/25)、12%(3/25)。
  • 晚期治疗相关G3胃肠、泌尿、血液学毒性发生率分别为0%(0/25)、0%(0/25)、4%(1/25),无G4-5毒性。
  • 中位随访24.7个月(自首次化疗起),野内复发1例(4%),野外腹主动脉旁复发4例(16%),远处复发4例(16%),癌症相关死亡2例(8%)。
  • 60%患者为III期,60%为3级;21/25完成6周期化疗,25/25完成大分割放疗。

临床怎么用

  • 对于局部晚期子宫内膜癌,术后辅助化疗后可采用大分割放疗25 Gy/5次,需关注血液学毒性。

局限性

  • 样本量小(25例),为单臂I期试验,随访时间有限,疗效需随机试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The safety and efficacy of hypofractionated radiation therapy (hypo-RT) and chemotherapy for locally advanced endometrial cancer is unknown. We evaluated the safety of hypo-RT sequenced after chemotherapy for patients with locally advanced endometrial cancer. METHODS AND MATERIALS: Patients with International Federation of Gynecology and Obstetrics 2009 stage III to IVA endometrioid adenocarcinoma, or any stage serous, clear cell, or carcinosarcoma of the uterus, were enrolled in this phase 1 trial (NCT#04386993). All patients underwent surgical staging and adjuvant chemotherapy followed by hypo-RT. Hypo-RT was intensity modulated RT 25 Gy/5 fractions delivered daily to the vaginal cuff and pelvis. The primary endpoint of this study was acute (first 90 days post-RT) and late (91 days to 12 months post-RT) high-grade (G3-5) gastrointestinal (GI), genitourinary (GU), and hematologic toxicities. Secondary endpoints included quality of life measures as well as in-field recurrence, locoregional control, distant control, disease-free survival, and overall survival. RESULTS: Twenty-five patients were enrolled, and all were evaluable for the primary endpoint. Notably, 60% had stage III disease and 60% had grade 3 disease. Most patients (21/25) completed 6 cycles of chemotherapy, and all patients (25/25) completed hypo-RT. The rate of acute treatment-related G3 GI, GU, and hematologic toxicity was 0% (0/25), 0% (0/25), and 12% (3/25). The rate of late treatment-related G3 GI, GU, and hematologic toxicity was 0% (0/25), 0% (0/25), and 4% (1/25). There were no G4-5 toxicities. At a median follow-up of 24.7 months from first chemotherapy treatment, there was 1 in-field recurrence (4%), 4 out-of-field paraortic recurrences (16%), 4 distant recurrences (16%), and 2 cancer-related deaths (8%). CONCLUSIONS: Hysterectomy followed by adjuvant chemotherapy and hypo-RT was safe. High-grade toxicities were low. This regimen may be worthy of evaluation in a randomized trial.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Schiff JP, Raju-Salicki S, McKinnish TR, et al. Phase I De-escalated RT in Endometrial Cancer. Int J Radiat Oncol Biol Phys. 2026. PMID: 41577208. doi:10.1016/j.ijrobp.2026.01.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。